To assess anti-tumor activity of sequential epirubicin/cyclophosphamide followed by
docetaxel with the randomized addition of celecoxib in HER2 negative patients or …

Background The REMAGUS-02 multicenter randomised phase II trial showed that the
addition to neoadjuvant chemotherapy (NAC) of trastuzumab in patients with localised …

Purpose To evaluate the combination of docetaxel, vinorelbine, and trastuzumab as
neoadjuvant therapy for human epidermal growth factor receptor 2 (HER2)–overexpressing …

Addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer may
improve pathological complete response (pCR) rates. We evaluated the efficacy and safety …

Background Pertuzumab is FDA approved in the preoperative setting in combination with
trastuzumab and chemotherapy, in women with nonmetastatic HER2+ breast cancer. The …

BACKGROUND: We tested the oral mammalian target of rapamycin (mTOR) inhibitor
everolimus in addition to paclitaxel in patients with HER2-negative tumours not responding …

Purpose To evaluate the efficacy and safety of neoadjuvant carboplatin and weekly
paclitaxel±weekly trastuzumab in resectable and locally advanced breast cancer. Patients …

To explore the impact of dose intensity (DI) in the adjuvant setting of breast cancer, a
randomized phase III trial was conducted comparing postoperative dose-dense sequential …

Objectives Trastuzumab (H) and pertuzumab (P) with standard chemotherapy is approved
for use in the neoadjuvant setting for human epidermal growth receptor 2‐positive patients …

Background This randomized phase III trial compared pathologic complete response (pCR)
rates of early breast cancer (EBC) following neoadjuvant epirubicin–docetaxel …